3034605-72-3
3034605-72-3
Chemical Structure
HVH-2930
- CAS No.: 3034605-72-3
- Formula:C29H36N4O3
- Molecular Weight:488.62
InChIKey: DBAWJYXZNCEOOW-UHFFFAOYSA-N
SMILES: O=C(C1=C(OC)C(C=CC(C)(C)O2)=C2C=C1)NC3=CC4=C(C=C3)C(C)=NN4CCC5CCN(C)CC5
Biological Activity: HVH-2930 is a HSP90 C-terminal domain inhibitor with high oral bioavailability. HVH-2930 downregulates HSP90 client proteins, inhibits the HER2 signaling pathway, induces apoptosis, and suppresses the proliferation of breast cancer cells. HVH-2930 inhibits the proliferation of tumors sensitive or resistant to Trastuzumab (HY-P9907). HVH-2930 is applicable to relevant research on breast cancer[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
HVH-2930 | 96.54% | HVH-2930 is a HSP90 C-terminal domain inhibitor with high oral bioavailability. HVH-2930 downregulates HSP90 client proteins, inhibits the HER2 signaling pathway, induces apoptosis, and suppresses the proliferation of breast cancer cells. HVH-2930 inhibits the proliferation of tumors sensitive or resistant to Trastuzumab (HY-P9907). HVH-2930 is applicable to relevant research on breast cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
